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INTRODUCTION
The development of bone marrow transplantation
(BMT) (initially for leukemias and subsequently for high-
dose therapy for malignant disease) has a long, complex, and
emotional history in the United States. US investigators
stake out positions before the phase 2 studies are even com-
plete. At least partly because of these ﬁrmly held opinions
and the way large randomized trials are funded in the
United States, few randomized trials of BMT or high-dose
therapy strategies have been completed in the United States.
The vast majority of the randomized data on BMT and
high-dose therapy is from Europe. Interestingly, in contrast,
2 large US randomized trials of high-dose chemotherapy for
breast cancer had actually completed accrual. Accrual on a
third was on target until the presentation of 5 rather mixed
randomized trials at the American Society of Clinical
Oncology (ASCO) meeting of 1999.
High-dose therapy for breast cancer has generated even
more heated reactions than high-dose therapy for other
malignancies, perhaps because breast cancer is a common
disease and thus the stakes are higher. Dr. Timothy John-
son, in a commentary on the television news program
20/20, began, “I will be reporting on one of the most con-
troversial and emotional episodes in the history of cancer
treatment—namely, the dramatic increase in the use of a
dangerous and expensive treatment for advanced breast
cancer before it was proven to be more effective than stan-
dard treatment.” He concluded “and here is the lesson we
must always remember from this saga: When a new, expen-
sive, and dangerous treatment is proposed, we must study it
carefully and pay for it only in controlled trials until we get
answers. We cannot allow emotions and political pressure
to determine medical treatment because lives are literally at
stake.” Interestingly, the choice of language adds to the
emotional level of discourse.
The events of the last year have been extraordinary.
Emotion and political pressure ware rampant, impeding dis-
passionate analysis of the available data. Arguments were
personal. Rather than improving US commitment to accrual
on randomized and appropriate pilot trials, accrual in the
only large US study virtually trickled to a halt.
Accusations leveled at high-dose therapy and transplan-
tation centers generally included the following:
• The high-dose studies in breast cancer research are
“disappointing,” “negative,” or “add nothing over con-
ventional therapy.”
• High-dose therapy for metastatic disease may not yet be
adequately evaluated in complete responders but is
clearly negative in partial responders.
• Randomized trials were inordinately delayed.
• American physicians have acted as if there were no need
for randomized trials.
• What constitutes “standard” adjuvant therapy has not
remained stagnant: even a positive high-dose trial would
need to be interpreted differently in the taxane era.
• Interest has now turned toward molecular-targeted
therapy.
• There is a threshold effect but no evidence for dose
response based on the National Surgical Adjuvant Breast
Program (NSABP) and Cancer and Leukemia Group B
(CALGB) adjuvant studies at conventional dose.
• The phase 2 studies were positive because of patient
selection.
• High-dose therapy is “dangerous and expensive.”
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• We must pay for high-dose therapy only in controlled
trials until we get answers. “In particular, conducting
pseudotrials that ‘test’ various high-dose drug combina-
tions is not justiﬁed given the current data” [1].
Sjoerd Rodenhuis, MD (Netherlands Working Party on
Autotransplants in Solid Tumors, Netherlands Cancer Insti-
tute, Amsterdam, The Netherlands), presenting the large
Dutch randomized study at ASCO 2000, commented that
attitudes toward high-dose adjuvant chemotherapy for
breast cancer went from “unreasonably high expectations
until 1999” to “unreasonably negative since 1999.”
THE DATA TO DATE
If we examine the actual data to date in light of these
accusations, we ﬁnd the following.
High-Dose Studies in Breast Cancer Studies Are
“Disappointing,” “Negative,” or “Add Nothing Over
Conventional Therapy”; High-Dose Therapy for
Metastatic Disease May Not Yet Be Adequately
Evaluated in Complete Responders but Is Clearly
Negative in Partial Responders
The 11 randomized published trials are summarized
below and in much more detail in the review by Nieto et al.
in this journal and by others [2,3]. Most investigators,
patients, and insurers would agree that the 2 South African
trials are uninterpretable, and that the Scandinavian trial
does not ask the question of high-dose therapy versus con-
ventional-dose therapy.
Only 2 of the 8 remaining studies randomized more
than 200 patients (783 patients for CALGB and 885 for the
Dutch study). Both have trends in relapse-free survival
favoring high-dose therapy. Because both studies were ﬁrst
presented at about 3 years of follow-up, significant differ-
ences may or may not emerge. Even these studies are mod-
est in size. In comparison, to detect the 1% difference favor-
ing paclitaxel, the recent CALGB adjuvant study required
about 3000 patients.
The Philadelphia trial—with 535 patients entered, 199
randomized, 184 analyzed, and only 164 receiving the
assigned treatment—is small, has imbalances, and further
compounds the comparison with a maintenance effect of up
to 2 years of conventional dose chemotherapy. In laboratory
models of breast cancer and other malignancies, dose of
chemotherapy correlates with curative therapy [4], whereas
cumulative dose is associated with survival [5]. This suggests
a strategy of using high doses when cure is the objective but
smaller doses over a prolonged period when palliation and
survival are the goal. (A combination of these strategies
might contribute to both the highest possible cure rate and
the longest survival for those who are not cured.)
Of the 5 studies with less than 100 patients, the 2 Duke
crossover studies clearly support high-dose therapy, and the
very small French trial has large differences supporting
high-dose therapy. The Dutch pilot study, widely heralded
as a negative study by those who discounted its lack of
power to detect a 30% difference, is now an object lesson in
biostatistics. The same group is now presenting their signiﬁ-
cantly positive planned analysis of their 285-patient subset
with about 6 years of follow-up.
Thus, no ﬁrm conclusions can be drawn from the metasta-
tic disease trials at all (even for partial responders), based purely
on the numbers of patients evaluated (Table 1). The data on
the only 2 reasonably sized randomized trials of adjuvant ther-
apy are far too immature to draw clinical conclusions.
Table 1. Eleven Randomized High-Dose Breast Cancer Studies*
Number Toxic Deaths, % Median 3-Year EFS, % 3-Year Survival, %
Randomized HDC Control Follow-Up, y HDC Control P HDC Control P Reference
Adjuvant 3
Dutch phase 3 885 0.9 0.2 3.5 72 65 .057 NA NA .31 [7,8]
First 284-patient subset 284 NA NA 7.0 77 62 .009 89 79 .039 [7,8]
CALGB Intergroup 783 7.4 0 3.6 71 64 NS 79 79 .29 [9]
South African (discredited)† 154 1.3 1.3 5.3 88 63 <.05 97 86 <.05 [10]
Dutch phase 2 pilot 81 0 0 4.1 70 65 .97 82 75 .84 [11]
M.D. Anderson Hospital 78 2.5 0 6.5 48 62 NS 58 77 NS [12]
Scandinavian (1 versus 6 525 0.7 0 2.0 68 62 NS 79 76 NS [13]
high-dose cycles)‡
Metastatic
Philadelphia Intergroup 184 1 0 3.1 6 12 .31 32 38 .23 [14]
Duke crossover studies§
Complete responders only 98 NA NA 6.3 25 10 <.01 33 38 .32 [15,16]
Bone metastases only 69 9.7 NA 4.9 17 0 <.01 28 22 NA [17]
South African (audit underway)† 90 0 0 6.0 18 4 <.05 18 4 <.05 [18]
French PEGASE 4 61 0 0 4.4 49 21 .06 55 28 .12 [19]
*Results of signiﬁcance and borderline signiﬁcance are shown in italic. EFS indicates event-free survival; HDC, high-dose chemotherapy; NA,
not available; CALGB, Cancer and Leukemia Group B; NS, not signiﬁcant; PEGASE, Programme d’Étude de la Greffe Autologue dans les Cancers
du Sein.
†The South African adjuvant study has been discredited, and the South African metastatic study is being audited [6]. 
‡The Scandinavian trial does not ask the question of high-dose therapy versus conventional-dose therapy. 
§Patients who relapsed on the conventional-dose arm then received high-dose chemotherapy. Data at 6.3 and 4.9 years’ median follow-up.
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Randomized Trials Were Inordinately Delayed
Studies in the late 1970s and early 1980s ﬁrst evaluated
single agents, then combinations in patients with advanced
refractory cancer (Table 2). Responses were observed sup-
porting the importance of dose, but were generally short:
disease-free survival was rare. Once toxicities could be antic-
ipated, and based on responses in cancer patients with
refractory disease, transplantation studies were offered to
women with untreated or responding metastatic breast can-
cer. Published reports began appearing in 1988-1992 [20-
23]. In an M.D. Anderson Hospital study, high-dose
cyclophosphamide, cisplatin, and etoposide were given with
and without stem cell support. The time to marrow recov-
ery was shorter using stem cell support [22].
A phase 2 trial using a ﬁrst-generation high-dose regi-
men in an adjuvant setting was published in 1993 with
promising disease-free survival but with a transplantation
mortality of 24% [24]. Additional phase 1 studies continued
to develop an effective regimen with lower regimen-related
mortality [25]. The availability after 1988 of hematopoietic
growth factors, such as granulocyte colony-stimulating fac-
tor (G-CSF) [26] and granulocyte-macrophage colony-stim-
ulating factor (GM-CSF) [27], modestly improved time to
marrow recovery in randomized trials [28,29]. The observa-
tion that stem cells could be mobilized after chemotherapy
and even more efficiently with growth factors [30] led to
substantially decreased aplasia, morbidity, and costs of auto-
transplant using stem cells and marrow [31] and then mobi-
lized stem cells alone [32].
Randomized metastatic and adjuvant trials were
designed with results ﬁrst reported in 1995 (South African)
and 2000, respectively [14,18]. 
Based on this progression of publications—and contrary
to commonly expressed criticism—clinical trials of high-
dose therapy in breast cancer proceeded to randomized eval-
uations expeditiously and responsibly. In fact, the use of a
ﬁrst-generation regimen for the US intergroup study, with
its mortality of 7.4%, may make detection of any differ-
ences, if they exist, more difﬁcult.
US Physicians Have Acted as if There Were No Need
for Randomized Trials
The willingness of Americans to participate in random-
ized trials is not the same as their willingness to apply results
from randomized trials. In the Autologous Blood and Mar-
row Transplant Registry (ABMTR) database, the number of
patients treated with high-dose therapy increased rapidly
after the startlingly positive South African randomized study
was published in 1995. The rush to transplantation slowed
in response to the presentation of the small negative ran-
domized Dutch and M.D. Anderson hospital studies pre-
sented at ASCO and published in Lancet, respectively, in
1998 [11,12,33] and then dropped precipitously with the
presentations of the 5 studies and the press coverage at
ASCO in 1999.
Thus, although Americans appear reluctant to participate
in randomized trials, the actual use of the high-dose strategy
has been exquisitely data driven—based on the only data avail-
able at the time the transplantations were being considered.
What Constitutes “Standard” Adjuvant Therapy Has
Not Remained Stagnant: Even a Positive High-Dose
Trial Would Need to Be Interpreted Differently in the
Taxane Era; Interest Has Now Turned Toward
Molecular-Targeted Therapy
The best current available data suggest about a 1% sur-
vival beneﬁt for adjuvant paclitaxel [34]. However, the 285-
patient Dutch study has about a 15% disease-free survival
advantage and a 10% survival advantage, with a cost in
terms of mortality of 1%. Thus, although the toxicity of
high-dose therapy exceeds that of the conventional dose of
paclitaxel, the survival difference is also considerably larger.
Furthermore, based on data showing a dose response for
taxanes, pilot trials studying whether the disease-free sur-
vival might be improved with different schedules of higher
taxane doses are perfectly reasonable [35-37].
Although we all enthusiastically anticipate more effective
molecularly based, targeted, and speciﬁc treatments for breast
cancer, they are not here yet. On arrival, they will require
evaluation, a process that will probably take some years. Bio-
logically based treatments such as Herceptin are not curative
in themselves, are unlikely to result in large survival differ-
ences, and apply only to a relatively small subset of women
with breast cancer. Again, Herceptin can easily be incorpo-
rated into high-dose regimens for appropriate women.
High-dose therapy is already here and partially evalu-
ated. If the 10% to 15% differences in survival and disease-
free survival in the analysis of the 285-patient Dutch trial
with 6-year follow-up are substantiated, some women would
elect such a treatment, given the low mortality. Effective
treatments generally become cost effective as physicians
become more experienced.
Finally, high-dose therapies have not remained stagnant,
either. New strategies—such as stem cell transplants
selected to deplete contaminating breast cancer cells,
sequential high-dose therapies, and studies of cell therapies
or vaccines using dendritic cells—are ongoing. The next
generation of studies may improve on the data presented in
the 2 articles in this journal. High-dose regimens already
incorporate new agents.
Table 2. History of the Development of High-Dose Regimens for Breast Cancer
Year Published Phase Breast Cancer Population Regimen Reference
1970-1988 1 Advanced refractory cancer Studies of single agents, then combinations —
1988-1992 2 Untreated or responding metastatic Combinations [20-23]
1993 2 Adjuvant First-generation high-dose regimens with transplantation [24]
1995 or 2000 3 Metastatic and adjuvant Randomized trials of combinations [14,18]
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There Is a Threshold Effect but No Evidence for Dose
Response Based on the NSAPB and CALGB Adjuvant
Studies at Conventional Dose
The first statistically robust positive study of higher
doses of adjuvant chemotherapy was conducted by the
CALGB (Table 3). Patients with node-positive breast cancer
were randomized to 1 of 3 doses of cyclophosphamide,
adriamycin, and ﬂuorouracil (CAF) [38]. The high-dose arm
involved CAF at doses of 600, 60, and 600 mg/m2, respec-
tively, and the low-dose arm was 300, 30, and 300 mg/m2. A
10% difference in the relapse-free curve developed by 2
years and has persisted through 10 years (ie, an approxi-
mately 20% reduction in mortality). This study has been
criticized because the low dose is lower than the current
standard dose and may be below a threshold dose required
for effect (ie, within the “no treatment” range). The dose
effect was seen most prominently in the 20% of patients
whose tumors overexpressed Her2/neu. For tumors without
Her2/neu overexpression, no dose effect was seen [39].
However, 2 studies of cyclophosphamide conducted by
the NSABP failed to show a dose effect for a doubling of the
cyclophosphamide dose with the doxorubicin dose held con-
stant, a 1.5-fold summation dose escalation [40,41]. Finally,
a 2-by-2 factorial study conducted by the CALGB failed to
show a dose effect for a 25% and a 50% increase in doxoru-
bicin dose (at most a 25% summation dose escalation) [34].
Thus, for the first positive CALGB study, all 3 agents
were increased 2-fold. In the second CALGB study, only the
doxorubicin was increased 1.5-fold, a difference probably
below the level of detection considering the dilutional effects
of the other 1 or 2 agents. At best, the dose intensity falls to a
1.25-fold increase, an effect that would defy detection in a
clinical trial. Because blood levels of most drugs vary about
2- to 3-fold, no signiﬁcant differences even in serum levels
emerge unless drug dosages are escalated substantially.
Thus, although a threshold effect is one reasonable
hypothesis, the lack of a signiﬁcant escalation of the summa-
tion dose intensity (as low as 13% in the CALGB study of
doxorubicin escalation) is also a reasonable and testable
hypothesis.
The Phase 2 Studies Were Positive Because of
Patient Selection
Patient selection applies to all studies. In the compari-
son of the CALGB and ABMTR database, the original
analysis for the abstract showed no difference in outcome
for patients with metastases. For this analysis, patients were
removed from the CALGB database who would not have
been candidates for high-dose therapy—such as those with
marrow involvement or no response to conventional therapy
and patients over age 60. However, when writing up the
analysis for the article, we discovered that the ABMTR
database included a significant proportion of patients who
were ineligible for the CALGB studies—patients who had
failed multiple prior regimens for metastatic disease. In fact,
58% of the patients in the CALGB database were not eligi-
ble for high-dose therapy, but 63% of the ABMTR patients
were not eligible for the CALGB studies (D.A. Berry, G.
Broadwater, J.P. Klein, K.A., J. Aisner, J. Bitran, M.
Costanza, C.O. Freytes, R.P. Gale, I.C. Henderson, H.M.
Lazarus, P.L. McCarthy, L. Norton, H. Parnes, A. Pecora,
M.C. Perry, P. Rowlings, G. Spitzer, M.H. Horowitz,
unpublished data). When patients who had failed multiple
prior treatment regimens were removed from the analysis,
the comparison showed a signiﬁcant survival advantage for
high-dose therapy. Certainly randomized studies are needed
to sort out these kinds of bias, but biases occur in both
directions.
High-Dose Therapy Is Dangerous and Expensive; We
Must Pay for It Only in Controlled Trials Until We
Get Answers; “In particular, conducting pseudotrials
that ‘test’ various high-dose drug combinations is not
justified given the current data” [1]
High-dose therapy is more risky than conventional-dose
therapy, but mortality is now 0% to 1% in most of the ran-
domized trials and is 2% in the article in this journal report-
ing on BCNU-containing regimens in experienced Califor-
nia centers. The management of advanced breast cancer is
expensive in itself. The costs of the last year of life are esti-
mated to be in the range of $45,000 and end in death. A reg-
Table 3. Randomized Adjuvant Studies of Chemotherapy Dose in Breast Cancer Without Stem Cell Support*
Summation Highest Dose Density
Drug Dose, mg/m2 Dose Arm Compared
Group Reference N CY Dox 5-FU Cycles, n Intensity,  With Lowest Outcome
CALGB [38] 1572 300 30 300 4 1.0 2-fold increase in DFS and survival in arms 2 and 3
400 40 400 6 2.0 each of 3 drugs significantly better than in arm 1
600 60 600 4 2.0
CALGB [34] 3170 600 60 — 4 1.0 1.5-fold increase No significant differences
600 75 — 4 1.13 of 1 of 2 drugs
600 90 — 4 1.25
NSABP B-22 [40] 2305 600 60 — 4 1.0 2-fold increase No significant differences
1200 60 — 2 1.0 in 1 of 2 drugs
1200 60 — 4 1.5
NSABP B-25 [41] 2548 1200 60 — 4 1.0 2-fold increase No significant differences
2400 60 — 2 1.0 of 1 of 2 drugs
2400 60 — 4 1.5
*CY indicates cyclophosphamide; Dox, doxorubicin; 5-FU, 5-ﬂuorouracil; CALGB, Cancer and Leukemia Group B; DFS, disease-free survival;
NSABP, National Surgical Adjuvant Breast Program.
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imen that improved survival by 10% would probably be
cost-effective (compared to dialysis as the benchmark).
The problems with coverage for high-dose therapy for
breast cancer emerged early in the phase 1 and 2 trials in the
late 1980s and early 1990s, when controlled randomized tri-
als had not yet even begun. Because women who were
turned down for coverage often received widespread press
coverage, laws were eventually passed requiring coverage for
any patient, not just those done on study. Coverage was
often actually easier to obtain for high-dose therapy as a
standard therapy rather than on study. Had the phase 1 and
2 clinical trials been covered, the randomized trials would
have begun in relative obscurity and could have been com-
pleted in the usual window of opportunity before the ﬁrst
randomized trial was published.
For-proﬁt transplantation centers cannot be blamed on
the transplantation community. Transplanters did not make
medical policy decisions regarding for-proﬁt transplantation
centers, for-proﬁt hospitals, or even for-proﬁt managed care
companies and cannot be blamed for any of them. Medical
policy regarding for-proﬁt medicine is made nationally and
is applicable to all of medicine.
In contrast to Miller and Sledge [1], I believe that can-
cer centers with an interest in high-dose therapy should
continue pilot phase 1 and 2 studies. Fortunately, cancer-
center programs with an expertise in high-dose therapy for
breast cancer—such as Duke, Hopkins, Stanford, Colorado,
Karmanos, M.D. Anderson, Columbia, and others—have
elected to continue their pilot studies to ensure that the reg-
imens evolve with the rest of medicine, incorporating new
drugs and strategies.
THE END OF THE BEGINNING: GOING FORWARD
High-dose chemotherapy trials for breast cancer have
now completed randomized evaluations of ﬁrst- and second-
generation high-dose regimens. Although the phase 3 stud-
ies available to date are small, the Dutch (885 patients) and
CALGB (783 patients) studies are of moderate size. Several
more reasonably large trials have already completed accrual.
We will eventually have data. Getting the right answer is
more important than demanding the answer prematurely.
Going forward, we will need to develop more effective
regimens. In the ABMTR, we have been unable to observe
signiﬁcant differences in outcome based on preparative regi-
mens, even despite large numbers [42]. In their review of
the literature in this issue of Biology of Blood and Marrow
Transplantation [16], Nieto et al. discuss the STAMP-V
(cyclophosphamide, thiotepa, and carboplatin [CTCb]) regi-
men; speciﬁcally, that thiotepa may induce the metabolism
of the prodrug cyclophosphamide, thus resulting in lower
levels of active metabolites. However, according to the Cali-
fornia study by Damon et al. [43] in this issue of Biology of
Blood and Marrow Transplantation, the CTCb regimen may
be superior to the other regimens used. In addition, the
toxic mortality was less than half that of the CBP
(cyclophosphamide, carmustine, and cisplatin, or STAMP-I)
regimen. The European modification of CTCb (with a
slightly decreased thiotepa dose and double the carboplatin
dose) in the Dutch study, again with a 1% mortality, pro-
duced signiﬁcant differences in disease-free and overall sur-
vival, which further suggests its efficacy. One explanation
may be that thiotepa is more active. The combination of
thiotepa and cyclophosphamide was supra-additive by
isobologram studies in breast cancer MCF7 cells [44]. Thus,
despite potentially lower concentration of cyclophos-
phamide, the addition of thiotepa—because of both its own
activity and supra-additivity with cyclophosphamide in com-
bination—still produces a better outcome. Clearly the clini-
cal result is important, not the drug level.
As we continue to design new trials, we must remain
aware of high-dose studies in other diseases. Certainly, the
following lessons learned from randomized trials of high-
dose therapy for intermediate- and high-grade lymphoma
should at least caution our interpretation of early breast can-
cer randomized trials.
• Good-risk patients do not benefit from high-dose
chemotherapy. The famous comment of Dr. George
Canellos (Dana Farber Cancer Institute, Boston, MA)
applies here: “You can only cure them once.”
• If there is signiﬁcant early BMT mortality, early analy-
ses will favor conventional-dose therapy; but differ-
ences, if they emerge, will become statistically signifi-
cant after approximately 4 to 7 years. (Certainly, if years
of follow-up are required in lymphoma studies, data in
breast cancer, a more indolent disease, may take even
longer to reliably emerge.)
• The US intergroup mechanism has not been particu-
larly interested in development and evaluation of BMT
trials. Lacking any other mechanism, US randomized
trials in lymphoma were completed only when funded
by the pharmaceutical industry. A mechanism for
designing and completing randomized high-dose trials
is under consideration by the National Heart, Lung, and
Blood Institute and the National Cancer Institute and
should be funded.
• Trials of high-dose chemotherapy versus maintenance
therapy in relapsed lymphoma are negative, whereas tri-
als of conventional-dose therapy followed by a high-
dose treatment versus observation or 1 more conven-
tional-dose treatment are positive. We may see this
pattern in breast cancer, as well.
• Induction therapy significantly improved disease-free
and overall survival in a French lymphoma study.
Finally, stem cell transplants are already being used to
deliver new biologically based therapies. Gene therapy or
immunotherapy may require stem cell transplantation tech-
nology. Ensuring the return of an uncontaminated marrow
may improve outcome as well.
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